Document is current
Any future updates will be listed below
-
Authors
Tran, Wen-Ching
Huynh, David
Chan, Tea
Chesla, Catherine A.
Park, Meyeon
-
Funding
Funding for this research was provided by:
University of California, San Francisco
National Institute of Diabetes and Digestive and Kidney Diseases (127421A)
UCSF PKD Center of Excellence (7027335)
- License Information
-
More Information
Article History
Received: 5 February 2017
Accepted: 26 June 2017
First Online: 5 July 2017
Ethics approval and consent to participate
: Ethics approval was obtained from the UCSF Committee on Human Research (CHR) Institutional Review Board. CHR number: 15–17,008. Signed informed consent to digitally record and extract data from interviews for analysis was obtained from each participant prior to the interview.
: Signed informed consent to digitally record and publish the interviews in a de-identified manner was obtained from each participant prior to the interview.
: Meyeon Park is the UCSF Site PI for the Tolvaptan REPRISE study.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
